Assessment of Drug-Drug Interactions between Daclatasvir and Methadone or Buprenorphine-Naloxone

被引:24
作者
Garimella, T.
Wang, R.
Luo, W. -L.
Wastall, P.
Kandoussi, H.
DeMicco, M. [1 ]
Bruce, R. D. [2 ,3 ]
Hwang, C.
Bertz, R.
Bifano, M.
机构
[1] Anaheim Clin Trials, Anaheim, CA USA
[2] Cornell Scott Hill Hlth Ctr, New Haven, CT USA
[3] Yale Univ, New Haven, CT USA
关键词
GENOTYPE; 1; INFECTION; REPLICATION COMPLEX INHIBITOR; HEPATITIS-C; OPIATE WITHDRAWAL; NS5A INHIBITOR; IN-VITRO; HCV; NORBUPRENORPHINE; METABOLISM; SOFOSBUVIR;
D O I
10.1128/AAC.00478-15
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Hepatitis C virus (HCV) infection is common among people who inject drugs, including those managed with maintenance opioids. Pharmacokinetic interactions between opioids and emerging oral HCV antivirals merit evaluation. Daclatasvir is a potent pangenotypic inhibitor of the HCV NS5A replication complex recently approved for HCV treatment in Europe and Japan in combination with other antivirals. The effect of steady-state daclatasvir (60 mg daily) on stable plasma exposure to oral opioids was assessed in non-HCV-infected subjects receiving methadone (40 to 120 mg; n = 14) or buprenorphine plus naloxone (8 to 24 mg plus 2 to 6 mg; n = 11). No relevant interaction was inferred if the 90% confidence interval (CI) of the geometric mean ratio (GMR) of opioid area under the plasma concentration-time curve over the dosing interval (AUC tau) or maximum concentration in plasma (C-max) with versus without daclatasvir was within literature-derived ranges of 0.7 to 1.43 (R- and S-methadone) or 0.5 to 2.0 (buprenorphine and norbuprenorphine). Dose-normalized AUC tau for R-methadone (GMR, 1.08; 90% CI, 0.94 to 1.24), S-methadone (1.13; 0.99 to 1.30), and buprenorphine (GMR, 1.37; 90% CI, 1.24 to 1.52) were within the no-effect range. The norbuprenorphine AUC tau was slightly elevated in the primary analysis (GMR, 1.62; 90% CI, 1.30 to 2.02) but within the no-effect range in a supplementary analysis of all evaluable subjects. Dose-normalized Cmax for both methadone enantiomers, buprenorphine and norbuprenorphine, were within the no-effect range. Standardized assessments of opioid pharmacodynamics were unchanged throughout daclatasvir administration with methadone or buprenorphine. Daclatasvir pharmacokinetics were similar to historical data. Coadministration of daclatasvir and opioids was generally well tolerated. In conclusion, these data suggest that daclatasvir can be administered with buprenorphine or methadone without dose adjustments.
引用
收藏
页码:5503 / 5510
页数:8
相关论文
共 40 条
[1]   Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection [J].
Afdhal, Nezam ;
Zeuzem, Stefan ;
Kwo, Paul ;
Chojkier, Mario ;
Gitlin, Norman ;
Puoti, Massimo ;
Romero-Gomez, Manuel ;
Zarski, Jean-Pierre ;
Agarwal, Kosh ;
Buggisch, Peter ;
Foster, Graham R. ;
Braeu, Norbert ;
Buti, Maria ;
Jacobson, Ira M. ;
Subramanian, G. Mani ;
Ding, Xiao ;
Mo, Hongmei ;
Yang, Jenny C. ;
Pang, Phillip S. ;
Symonds, William T. ;
McHutchison, John G. ;
Muir, Andrew J. ;
Mangia, Alessandra ;
Marcellin, Patrick .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20) :1889-1898
[2]   Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection [J].
Afdhal, Nezam ;
Reddy, K. Rajender ;
Nelson, David R. ;
Lawitz, Eric ;
Gordon, Stuart C. ;
Schiff, Eugene ;
Nahass, Ronald ;
Ghalib, Reem ;
Gitlin, Norman ;
Herring, Robert ;
Lalezari, Jacob ;
Younes, Ziad H. ;
Pockros, Paul J. ;
Di Bisceglie, Adrian M. ;
Arora, Sanjeev ;
Subramanian, G. Mani ;
Zhu, Yanni ;
Dvory-Sobol, Hadas ;
Yang, Jenny C. ;
Pang, Phillip S. ;
Symonds, William T. ;
McHutchison, John G. ;
Muir, Andrew J. ;
Sulkowski, Mark ;
Kwo, Paul .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (16) :1483-1493
[3]  
[Anonymous], 75 ANN M COLL PROBL
[4]  
[Anonymous], 2015, 16 INT WORKSH CLIN P
[5]  
[Anonymous], 49 ANN M EUR ASS STU
[6]  
Bifano M, 2013, 8 INT WORKSH CLIN PH
[7]   An Open-Label Investigation into Drug-Drug Interactions Between Multiple Doses of Daclatasvir and Single-Dose Cyclosporine or Tacrolimus in Healthy Subjects [J].
Bifano, Marc ;
Adamczyk, Robert ;
Hwang, Carey ;
Kandoussi, Hamza ;
Marion, Alan ;
Bertz, Richard J. .
CLINICAL DRUG INVESTIGATION, 2015, 35 (05) :281-289
[8]   Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate [J].
Bifano, Marc ;
Sevinsky, Heather ;
Hwang, Carey ;
Kandoussi, Hamza ;
Jiang, Hao ;
Grasela, Dennis ;
Bertz, Richard .
ANTIVIRAL THERAPY, 2014, 19 (05) :511-519
[9]   Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir [J].
Bifano, Marc ;
Hwang, Carey ;
Oosterhuis, Berend ;
Hartstra, Jan ;
Grasela, Dennis ;
Tiessen, Renger ;
Velinova-Donga, Maria ;
Kandoussi, Hamza ;
Sevinsky, Heather ;
Bertz, Richard .
ANTIVIRAL THERAPY, 2013, 18 (07) :931-940
[10]   Methadone as HIV prevention: High Volume Methadone Sites to decrease HIV incidence rates in resource limited settings [J].
Bruce, R. Douglas .
INTERNATIONAL JOURNAL OF DRUG POLICY, 2010, 21 (02) :122-124